These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24437251)

  • 1. [Potentials for the combined therapy of urination disorders in men: the choice of optimal scheme of treatment].
    Golubtsova EN; Tomilov AA; Veliev EI
    Urologiia; 2013; (5):96-8, 100-1. PubMed ID: 24437251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.
    Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
    Int J Urol; 2014 Dec; 21(12):1258-62. PubMed ID: 25039474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostatic and extraprostatic alpha-adrenoceptors--contributions to the lower urinary tract symptoms in benign prostatic hyperplasia.
    Andersson KE
    Scand J Urol Nephrol Suppl; 1996; 179():105-11. PubMed ID: 8908675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?
    Barendrecht MM; Abrams P; Schumacher H; de la Rosette JJ; Michel MC
    Neurourol Urodyn; 2008; 27(3):226-30. PubMed ID: 17638312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Male lower urinary tract symptoms: treatment with a-blockers, 5-a-reductase inhibitors, antimuscarinics, or a combination.
    Appell RA
    Curr Urol Rep; 2007 Sep; 8(5):370-2. PubMed ID: 17880835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A practical approach to the management of lower urinary tract symptoms among men.
    Woo HH; Gillman MP; Gardiner R; Marshall V; Lynch WJ
    Med J Aust; 2011 Jul; 195(1):34-9. PubMed ID: 21728939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Generally effective for unstable bladder? Tamsulosin: application not limited to benign prostatic hyperplasia].
    Urologe A; 2003 Feb; 42(2):301-2. PubMed ID: 12739514
    [No Abstract]   [Full Text] [Related]  

  • 8. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials.
    Kortmann BB; Floratos DL; Kiemeney LA; Wijkstra H; de la Rosette JJ
    Urology; 2003 Jul; 62(1):1-9. PubMed ID: 12837408
    [No Abstract]   [Full Text] [Related]  

  • 9. [Benign prostate hyperplasia: success and limitations of pharmacological therapy].
    Madersbacher S; Marszalek M
    Internist (Berl); 2007 Oct; 48(10):1157-64. PubMed ID: 17426942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination drug therapy in patients with BPH].
    Kuzmenko AV; Kuzmenko VV; Gyaurgiev TA
    Urologiia; 2018 Mar; (1):101-105. PubMed ID: 29634142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical and urodynamic evaluation of efficacy of conservative treatment of urination disorders in patients with benign prostate hyperplasia].
    Danilov VV; Danilova TI; Danilov VV; Danilov VV
    Urologiia; 2013; (5):55-8. PubMed ID: 24437242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change in parameters before and after alpha-1-blocker therapy for men with lower urinary tract symptoms using color doppler ultrasound urodynamics: possible application for prediction of clinical outcome.
    Watanabe Y; Yokoyama T; Ozawa H; Nishiguchi J; Nose H; Kumon H
    Urol Int; 2004; 73(3):252-7. PubMed ID: 15539846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical management of lower urinary tract symptoms in men: current treatment and future approaches.
    Patel AK; Chapple CR
    Nat Clin Pract Urol; 2008 Apr; 5(4):211-9. PubMed ID: 18301417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Storage and voiding symptoms: pathophysiologic aspects.
    Andersson KE
    Urology; 2003 Nov; 62(5 Suppl 2):3-10. PubMed ID: 14662401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management.
    Barkin J
    Can J Urol; 2011 Apr; 18 Suppl():14-9. PubMed ID: 21501546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benign prostatic hyperplasia - progress in pathophysiology and management.
    Dobrek Ł; Thor PJ
    Pol Merkur Lekarski; 2015 Nov; 39(233):263-70. PubMed ID: 26637089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Surgery (TUR-P) as a recommended initial treatment modality for the presented case].
    Gotoh M
    Hinyokika Kiyo; 2005 Sep; 51(9):603-8. PubMed ID: 16229373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alpha adrenergic blocking agents in disorders of the bladder sphincter].
    Perrigot M; Vannier A; Bor Y
    Rev Prat; 1986 Jan; 36(5):223-8. PubMed ID: 2421393
    [No Abstract]   [Full Text] [Related]  

  • 20. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists.
    Andersson KE
    World J Urol; 2002 Apr; 19(6):390-6. PubMed ID: 12022707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.